"I know physicians are busy, but I’m treating a patient, not a disease. I take a holistic approach. I think we need to make physicians who treat chronic myeloid leukemia treat the disease and make ...

Scemblix showed a 68% major molecular response rate at 48 weeks, outperforming tyrosine kinase inhibitors by 19%. Common side effects included rash, musculoskeletal pain, and fatigue, with laboratory ...

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- including both accelerated or myeloid blast phases of the ...

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

The advent of tyrosine kinase inhibitors (TKIs) has radically altered the outcome of patients with chronic myeloid leukemia (CML). Patients with chronic-phase disease can now expect a 10-year survival ...

Scemblix outperformed standard TKIs in 96-week MMR rates, showing significant efficacy in CML treatment. FDA accelerated approval was based on 48-week data, highlighting Scemblix's early promise.

—In Europe, patients with Philadelphia chromosome-positive CML generally have better rates of survival than similar patients in the U.S. These investigators at MD Anderson Cancer Center tried to ...

The latest research on chronic myeloid leukemia (CML) presented at the 2024 American Society of Hematology 2024 Annual Meeting and Exposition is reported by Dr Jorge Cortes from Georgia Cancer Center ...

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...